
    
      This is a Phase 2, single arm open-label clinical study in up to 10 participants that will
      consist of screening period (which may include a titration of maximum dose/maximally
      tolerated dose of angiotensin converting enzyme (ACE) and/or angiotensin II receptor blocker
      (ARB)), a 24-week treatment period and a 12-week post-treatment follow-up evaluation period.
    
  